Fibrinolytic Capacity of Desmoteplase Compared to Tissue Plasminogen Activator in Rabbit Eyes
| Autor: | Simon A. Pot, Katrin Voelter, Christoph Tappeiner, Fernando Laguna Sanz, Deborah Bruetsch, Karina Klein, Nicole Borel |
|---|---|
| Přispěvatelé: | University of Zurich, Voelter, Katrin |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Administration Topical 10184 Institute of Veterinary Pathology Pharmacology Eye Tissue plasminogen activator Fibrin Plasminogen Activators 03 medical and health sciences 0302 clinical medicine Fibrinolytic Agents In vivo medicine 2736 Pharmacology (medical) Animals Desmoteplase Pharmacology (medical) 610 Medicine & health 630 Agriculture Dose-Response Relationship Drug biology business.industry Rabbit (nuclear engineering) 2731 Ophthalmology medicine.disease 10226 Department of Molecular Mechanisms of Disease Ophthalmology 3004 Pharmacology 030104 developmental biology Tissue Plasminogen Activator Toxicity 030221 ophthalmology & optometry biology.protein 570 Life sciences Female 10090 Equine Department Rabbits Injections Intraocular Ophthalmic Solutions business Uveitis medicine.drug |
| Zdroj: | Journal of Ocular Pharmacology and Therapeutics. 35:66-75 |
| ISSN: | 1557-7732 1080-7683 |
| DOI: | 10.1089/jop.2018.0070 |
| Popis: | PURPOSE Desmoteplase (DSPA) was evaluated and compared with tissue plasminogen activator (t-PA) for its intraocular fibrinolytic effect and short-term toxicity in an in vivo study using rabbit eyes. METHODS Fibrin clots were induced in the anterior chamber of 44 rabbit eyes, and drug efficacy was measured by clot size reduction over 24 h. Topical DSPA eye drops (1.4 and 2 mg/mL) were compared with vehicle solution in a multiple-drop regimen in 8 animals per group. Intracameral injections of 0.6 μg DSPA (n = 14) and 25 μg t-PA (n = 14) were evaluated for their fibrinolytic efficacy. Animals were euthanized 24 h after drug application. RESULTS No significant differences were seen between topically treated DSPA and vehicle-treated animals. Intracameral t-PA had a higher fibrinolytic efficacy than DSPA at early time points, but no significant difference was seen between both groups at 24-h postapplication. Animals with t-PA treatment demonstrated significantly more side effects compared with DSPA-treated animals. DSPA showed no-to-mild side effects after topical and intracameral treatment. Histologically, no toxic effects were observed in any globe. CONCLUSIONS DSPA is a promising drug with fewer side effects and similar fibrinolytic efficacy compared with t-PA 24 h after intracameral application in rabbit eyes at the tested concentration. Drug efficacy might be improved by increasing intracameral DSPA doses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|